CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Gamma tACS (40 Hz) over the superior parietal cortex +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04842955
NCT04842955N/ACompleted

Interventional Cross-over Study to Evaluate the Modulators of Efficacy of Alternating Current Brain Stimulation (tACS) in Patients With Alzheimer's Disease

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·interventional·Posted Apr 13, 2021·Updated Nov 21, 2022

In Brief

A clinical study evaluating Gamma tACS (40 Hz) over the superior parietal cortex and Sham tACS over the superior parietal cortex for Alzheimer Disease. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as "oscillopathies". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances. Transcranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory. On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease. In this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 13, 2021
Enrollment StartMar 10, 2021
Primary CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.2 years ago

Interventions

Gamma tACS (40 Hz) over the superior parietal cortexdevice

Single session of gamma tACS (40 Hz) over the superior parietal cortex

Sham tACS over the superior parietal cortexdevice

Single session of sham tACS over the superior parietal cortex